

Edgar Filing: NOVARTIS AG - Form 6-K

NOVARTIS AG  
Form 6-K  
July 16, 2002

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 or 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934

Report on Form 6-K dated July 16, 2002

Novartis AG  
(Name of Registrant)

Lichtstrasse 35  
4056 Basel  
Switzerland  
-----

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file  
annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

Enclosure: Reminder - Invitation for Telephone Conference, First Half 2002 Sales  
& Results.

Investor Relations

Novartis International AG  
CH-4002 Basel  
Switzerland  
Karen J Huebscher, PH.D.  
Tel +41 61 324 8433  
Nafida Bendali

[LOGO]

Edgar Filing: NOVARTIS AG - Form 6-K

Tel +41 61 324 3514  
Sabine Moravi, MBA  
Tel + 41 61 324 8989  
Fax + 41 61 324 8844  
Silke Zentner  
Tel + 41 61 324 8612  
Francisco Bouzas  
Tel + 41 61 324 2462  
Fax + 41 61 324 8844  
Internet Address:  
<http://www.novartis.com>

REMINDER

- INVITATION FOR TELEPHONE CONFERENCE -

First Half 2002 Sales & Results

Dear Investor

We are pleased to invite you to our First Half Sales & Results 2002 conference call. Please below the following dial-in numbers:

Date: Monday, July 22, 2002

Time: Advisable: dial-in 10 minutes before

06.00 p.m. Switzerland

05.00 p.m. UK

12.00 p.m. New York

Advisable: dial-in 10 minutes before

Phone numbers: +41 91 610 4111 or toll-free +800 2467 8700 Europe and ROW

+1 800 860 2442 US

You may access the conference call as a live audio webcast on the Internet on July 22: <http://www.novartis.com/investors> (under upcoming event). This information is now available for tests and for the submission of questions in advance.

Additional financial information will be available on Monday, July 22, on the Internet <http://www.novartis.com/investors>

Playback for 48 hours

Date: Monday, July 22, 2002

Time: 07.00 p.m. Switzerland

06.00 p.m. UK

01.00 p.m. New York

Phone numbers: +41 91 612 43 30 Europe and ROW

+1 877 344 7529 US

Edgar Filing: NOVARTIS AG - Form 6-K

Code: 335 (followed by the # sign)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novartis AG

Date: July 16, 2002

By: /s/ Malcolm B. Cheetham

Name: Malcolm B. Cheetham

Title: Head Group Financer  
Group Fin. Reporting and Accounting